A New Genome Engineering Platform
Powered by the learnings of more than 500,000 edits, EditCo's automated CRISPR platform is enabling better, faster, & more consistent gene editing for tomorrow's groundbreaking discoveries.
Edited-to-order cells
A Gold-Standard for Scalable, Consistent Genome Engineering
Leveraging a sophisticated infrastructure with integration between bioinformatics, software, and automated platforms
Automating biology and synergistic disciplines for streamlined cell editing and cell culture workflows
Delivering experiment-ready edited cells for your next discoveries through a robust and cohesive ecosystem
Higher-Quality CRISPR Reagents
Consistent, Quality CRISPR Reagents at Unparalleled Speeds
We are here to accelerate answers to your critical research by providing access to reproducible and high-quality CRISPR gRNAs at unparalleled speeds, through the use of a robust automated inventory management and fulfillment platform.
Faster Turnaround Times
Robust automation allows for delivery of CRISPR reagents in as fast as 5 days, enabling discoveries at the speed of research.
Scalable Precision
Strict quality control combined with intelligent design enables precision high-throughput experiments to fit today's scientific landscape.
Lorem Overline
Testimonials consectitur amet sed
Congue fermentum eros leo commodo. Integer vitae vitae ac amet. Vitae sed lectus vel lacus adipiscing nulla facilisis mauris porttitor. Viverra elementum odio vitae id.
Albert Rose, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Viverra aliquam volutpat interdum quisque vel mattis. Malesuada aliquam egestas pharetra a tempus ullamcorper egestas.
Amanda Peyton, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute
Nibh luctus pulvinar sagittis faucibus commodo vitae purus. Ullamcorper dictum.
Joseph James, Ph. D.
Principal Investigator, Boston Children's Hospital
Congue fermentum eros leo commodo. Integer vitae vitae ac amet. Vitae sed lectus vel lacus adipiscing nulla facilisis mauris porttitor. Viverra elementum odio vitae id.
Albert Rose, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Congue fermentum eros leo commodo. Integer vitae vitae ac amet. Vitae sed lectus vel lacus adipiscing nulla facilisis mauris porttitor. Viverra elementum odio vitae id.
Albert Rose, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Congue fermentum eros leo commodo. Integer vitae vitae ac amet. Vitae sed lectus vel lacus adipiscing nulla facilisis mauris porttitor. Viverra elementum odio vitae id.
Albert Rose, Ph. D.
Principal Investigator, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Resources
EditCo's CRISPR Platform in Action
On-Demand Webinar
AI-driven Identification and Validation of Novel Synthetic Lethal Gene Pairs
Learn how EditCo Bio’s automated CRISPR platform is advancing drug discovery via Evariste's AI-driven platform.
Watch Now
article
A New Research Toolbox at the Forefront of Genomic Engineering
How EditCo Bio’s novel CRISPR platform is changing cell and gene therapy research.
Read More
On-Demand Webinar
Ensuring Cell Health for Optimal Research Outcomes and Successful CRISPR Gene Editing Experiments
Learn about the latest technologies in cell health assessment, and how cell health influences effective, scalable CRISPR cell engineering.
Watch Now
poster
Rapid and Efficient Genome Editing for Human Primary T-Cells
EditCo can quickly provide functional, stable, made-to-order edited T-cells from a variety of prevalidated donors using our genome engineering platform.
Read More